Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

First Posted Date
2005-04-25
Last Posted Date
2007-05-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
100
Registration Number
NCT00109096
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-03-21
Last Posted Date
2009-07-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
514
Registration Number
NCT00105989
Locations
🇸🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sundsvall, Sweden

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

First Posted Date
2005-03-21
Last Posted Date
2009-06-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
37
Registration Number
NCT00106002
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Phase 2
Completed
Conditions
First Posted Date
2005-03-07
Last Posted Date
2007-05-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
50
Registration Number
NCT00105092
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Houston, Texas, United States

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Phase 4
Completed
Conditions
First Posted Date
2005-02-11
Last Posted Date
2007-11-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
600
Registration Number
NCT00103571
Locations
🇵🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rio Piedras, Puerto Rico

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2005-02-02
Last Posted Date
2014-12-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
663
Registration Number
NCT00102804
Locations
🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2005-01-26
Last Posted Date
2007-11-30
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
77
Registration Number
NCT00102219
Locations
🇻🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caracas, Venezuela

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Phase 1
Completed
Conditions
First Posted Date
2005-01-17
Last Posted Date
2006-08-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
61
Registration Number
NCT00101842
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas, United States

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Phase 4
Completed
Conditions
First Posted Date
2005-01-07
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
600
Registration Number
NCT00100776
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Raleigh, North Carolina, United States

🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tacoma, Washington, United States

🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5-hours, EST), or speak with your personal physician, Clementon, New Jersey, United States

Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2004-12-16
Last Posted Date
2007-12-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
97
Registration Number
NCT00099515
Locations
🇿🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa

© Copyright 2024. All Rights Reserved by MedPath